Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoDSKYF -4.01% Interest Coverage is 26.34 as of Jun. 2026, which is 47% above its 10-year median of 17.92. The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, Daiichinkyo Co ranks better than 60.41% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Daiichinkyo Co's
Operating Income
for the
three
months ended in Jun. 2026 was $529 Mil. Daiichinkyo Co's Interest Expense for the
three
months ended in Jun. 2026 was $-20 Mil.
Daiichinkyo Co's interest coverage for the quarter that ended in Jun. 2026 was 26.34.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Daiichinkyo Co's Interest Coverage or its related term are showing as below:
DSKYF'
s Interest Coverage Range Over the Past 10 Years
Min: 11.53 Med: 17.92 Max: 35.11
Current: 22.2
DSKYF's Interest Coverage is ranked better than 60.41% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.7
vs DSKYF: 22.20
Daiichinkyo Co (OTCPK:DSKYF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Daiichinkyo Co Interest Coverage Related Terms
Daiichinkyo Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
DSKYF vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (DSKYF) has a Interest Coverage of 26.34 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Daiichinkyo Co and its competitors. This is 47% above median its historical median of 17.92. Over the past decade, Daiichinkyo Co's Interest Coverage has ranged from 11.53 to 35.11. According to the industry distribution chart, Daiichinkyo Co ranks #272 out of 687 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is Daiichinkyo Co's Interest Coverage too high?
Daiichinkyo Co's current Interest Coverage of 26.34 is 47% above median its 10-year median of 17.92. Over the past 10 years, this metric has ranged from a low of 11.53 to a high of 35.11. The Drug Manufacturers industry median Interest Coverage is 12.70. Daiichinkyo Co's value of 26.34 is 107.4% above this industry median. Based on the distribution chart, Daiichinkyo Co ranks #272 out of 687 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Daiichinkyo Co's Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #272 out of 687 companies for Interest Coverage. This puts Daiichinkyo Co in the upper half of its industry. The industry median Interest Coverage is 12.70. Daiichinkyo Co's value of 26.34 is 107.4% above this benchmark. Historically, Daiichinkyo Co's own Interest Coverage has ranged from 11.53 to 35.11 over the past decade. While the company's 10-year median is 17.92 vs. the industry median of 12.70, Daiichinkyo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.70, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current Interest Coverage of 26.34 is 107.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current Interest Coverage is 26.34, which is 47% above median its own 10-year median of 17.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $33.49, compared to a current price of $15.94 — trading 52.4% below its estimated fair value. The current Interest Coverage is 26.34, which is 47% above median its 10-year median of 17.92 and 107.4% above the Drug Manufacturers industry median of 12.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current Interest Coverage is 26.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSKYF has been successfully added to your 
